Represents Grant table in the DB

GET /v1/grants?page%5Bnumber%5D=1392&sort=-program_officials
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/vnd.api+json
Vary: Accept

{
    "links": {
        "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials",
        "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-program_officials",
        "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-program_officials",
        "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-program_officials"
    },
    "data": [
        {
            "type": "Grant",
            "id": "8090",
            "attributes": {
                "award_id": "75N92021C00001-P00004-9999-1",
                "title": "TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Biomedical Imaging and Bioengineering (NIBIB)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-22",
                "end_date": "2022-12-31",
                "award_amount": 590553,
                "principal_investigator": {
                    "id": 23976,
                    "first_name": "MILAN",
                    "last_name": "PATEL",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1095,
                            "ror": "",
                            "name": "PATHOGENDX",
                            "address": "",
                            "city": "",
                            "state": "AZ",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1095,
                    "ror": "",
                    "name": "PATHOGENDX",
                    "address": "",
                    "city": "",
                    "state": "AZ",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing  lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates.  What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months.   Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.",
                "keywords": [
                    "COVID-19",
                    "Cost Savings",
                    "Exercise",
                    "Performance at work",
                    "Quantitative Reverse Transcriptase PCR",
                    "RADx",
                    "RADx Tech",
                    "Slide",
                    "System",
                    "Technology",
                    "Testing",
                    "Time",
                    "Update",
                    "cost",
                    "variant detection"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8091",
            "attributes": {
                "award_id": "75N93020D00007-0-759302100001-1",
                "title": "Nonhuman Primate Studies Coordination Center (NHP CC) to Support COVID-related Research at the National Primate Research Centers (NPRCs)",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-01",
                "end_date": "2024-07-31",
                "award_amount": 1676937,
                "principal_investigator": {
                    "id": 6569,
                    "first_name": "JAY",
                    "last_name": "RAPPAPORT",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 811,
                            "ror": "",
                            "name": "TULANE UNIVERSITY OF LOUISIANA",
                            "address": "",
                            "city": "",
                            "state": "LA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 811,
                    "ror": "",
                    "name": "TULANE UNIVERSITY OF LOUISIANA",
                    "address": "",
                    "city": "",
                    "state": "LA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "In response to the National Emergency related to the COVID-19 pandemic and the need to prioritize studies to support the Acceleration of COVID-19 Therapeutic Interventions and Vaccines (ACTIV), the National Institute of Allergy and Infectious Disease (NIAID) will establish a Nonhuman Primate Studies Coordination Center (NHP CC) to aid in the distribution, administration, and coordination of COVID Nonhuman Primate (NHP) studies across the seven National Primate Resource Centers (NPRCs). This network of NPRCs will directly support three of the four fast-track focus areas in ACTIV. 1.\tStandardize and share preclinical evaluation methods in an open forum that allows for comparison and validation.  2.\tPrioritize and accelerate clinical evaluation of therapeutic candidates with near-term potential.  3.\tAdvance vaccine development.  The NHP CC shall coordinate activities at each Nonhuman Primate COVID Therapeutics and Vaccine Evaluation Unit (NHP CoTVEU) and establish lines of communications among all parties.",
                "keywords": [
                    "Acceleration",
                    "Area",
                    "COVID-19",
                    "COVID-19 pandemic",
                    "COVID-19 therapeutics",
                    "Communication",
                    "Contractor",
                    "Emergency Situation",
                    "Methods",
                    "National Institute of Allergy and Infectious Disease",
                    "Primates",
                    "Research",
                    "Resources",
                    "Standardization",
                    "Therapeutic Intervention",
                    "Validation",
                    "coronavirus disease",
                    "coronavirus therapeutics",
                    "nonhuman primate",
                    "preclinical evaluation",
                    "programs",
                    "research clinical testing",
                    "response",
                    "therapeutic candidate",
                    "therapeutic evaluation",
                    "therapeutic vaccine",
                    "vaccine development",
                    "vaccine evaluation"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8095",
            "attributes": {
                "award_id": "75N92021P00053-0-0-1",
                "title": "RADX TECH PROJECT - WORK PACKAGE 1 SUPPORT",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Biomedical Imaging and Bioengineering (NIBIB)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-04",
                "end_date": "2022-02-03",
                "award_amount": 250000,
                "principal_investigator": {
                    "id": 23979,
                    "first_name": "PING",
                    "last_name": "WANG",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 232,
                            "ror": "https://ror.org/00b30xv10",
                            "name": "University of Pennsylvania",
                            "address": "",
                            "city": "",
                            "state": "PA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 232,
                    "ror": "https://ror.org/00b30xv10",
                    "name": "University of Pennsylvania",
                    "address": "",
                    "city": "",
                    "state": "PA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "We propose to detect acute SARS-CoV-2 infections using a sample-to-answer portable device detecting very low concentrations of viral antigens using our patented microbubbling digital assay technology.",
                "keywords": [
                    "Acute",
                    "Biological Assay",
                    "Devices",
                    "Legal patent",
                    "RADx Tech",
                    "SARS-CoV-2 infection",
                    "Sampling",
                    "Technology",
                    "Viral Antigens",
                    "Work",
                    "digital",
                    "portability"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8097",
            "attributes": {
                "award_id": "75N92021C00003-P00002-9999-1",
                "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Biomedical Imaging and Bioengineering (NIBIB)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-01",
                "end_date": "2023-01-31",
                "award_amount": 2500000,
                "principal_investigator": {
                    "id": 23980,
                    "first_name": "TODD",
                    "last_name": "WOODRICH",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": null,
                "abstract": "Resubmission of Application 3136.   This product concept has been updated to include Flu viral targets along with SARS-CoV-2.  The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020.  The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.",
                "keywords": [
                    "2019-nCoV",
                    "Acute",
                    "Biological Assay",
                    "COVID-19 assay",
                    "COVID-19 patient",
                    "Clinical",
                    "Communicable Diseases",
                    "Computer software",
                    "Coupled",
                    "Detection",
                    "Molecular",
                    "Patients",
                    "RADx Tech",
                    "RNA Sequences",
                    "Reporting",
                    "Running",
                    "Seasons",
                    "Specimen",
                    "Technology",
                    "Time",
                    "Update",
                    "Viral",
                    "Virus",
                    "Virus Diseases",
                    "base",
                    "betacoronavirus",
                    "flu",
                    "instrument",
                    "respiratory",
                    "waiver"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8098",
            "attributes": {
                "award_id": "75N92021C00003-0-9999-1",
                "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Biomedical Imaging and Bioengineering (NIBIB)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-01",
                "end_date": "2022-01-31",
                "award_amount": 5505000,
                "principal_investigator": {
                    "id": 23980,
                    "first_name": "TODD",
                    "last_name": "WOODRICH",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": null,
                "abstract": "Resubmission of Application 3136.   This product concept has been updated to include Flu viral targets along with SARS-CoV-2.  The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020.  The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.",
                "keywords": [
                    "2019-nCoV",
                    "Acute",
                    "Biological Assay",
                    "COVID-19 assay",
                    "COVID-19 patient",
                    "Clinical",
                    "Communicable Diseases",
                    "Computer software",
                    "Coupled",
                    "Detection",
                    "Molecular",
                    "Patients",
                    "RADx Tech",
                    "RNA Sequences",
                    "Reporting",
                    "Running",
                    "Seasons",
                    "Specimen",
                    "Technology",
                    "Time",
                    "Update",
                    "Viral",
                    "Virus",
                    "Virus Diseases",
                    "base",
                    "betacoronavirus",
                    "flu",
                    "instrument",
                    "respiratory",
                    "waiver"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8099",
            "attributes": {
                "award_id": "75N92021C00007-0-9999-1",
                "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROGRAM - PROJECT #6658",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Biomedical Imaging and Bioengineering (NIBIB)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-02-02",
                "end_date": "2022-02-01",
                "award_amount": 10295000,
                "principal_investigator": {
                    "id": 23981,
                    "first_name": "DAVID",
                    "last_name": "YOO",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1672,
                            "ror": "",
                            "name": "GENBODY INC.",
                            "address": "",
                            "city": "",
                            "state": "",
                            "zip": "",
                            "country": "KOREA REP OF",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1672,
                    "ror": "",
                    "name": "GENBODY INC.",
                    "address": "",
                    "city": "",
                    "state": "",
                    "zip": "",
                    "country": "KOREA REP OF",
                    "approved": true
                },
                "abstract": "A method was developed to detect not only SARS-CoV-2, but also influenza A and Influenza B anigen at the same time in a single lateral flow rapid testing (LFRT) system. The kit is a single device that can detect SARS-CoV-2 antigen and influenza antigen simultaneously.  Since Influenza with respiratory illness with symptoms of high fever is similar to COVID-19, there are many difficulties to distinguish it from clinical diagnosis. Influenza can be treated with antiviral drugs such as Tamiflu, and there are also defense measures such as vaccines, so the treatment method is different. We have developed and evaluated an analytical/clinical performance for rapid diagnosis kit of SARS-CoV-2 antigen, obtained approval from the Korean Food and Drug Administration, and diagnostic Kits for influenza A/B antigen have also been licensed and commercialized. This diagnostic kit is basically diagnosed through the naked eye, and a portable equipment (Confiscope G20 has CE but no FCC) can be used for accurate determination which can be applied to control systems using a network.",
                "keywords": [
                    "2019-nCoV",
                    "Antigens",
                    "Antiviral Agents",
                    "COVID-19",
                    "COVID-19 detection",
                    "Clinical",
                    "Devices",
                    "Diagnosis",
                    "Diagnostic Reagent Kits",
                    "Equipment",
                    "Eye",
                    "Fever",
                    "Influenza",
                    "Influenza A virus",
                    "Influenza B Virus",
                    "Koreans",
                    "Lateral",
                    "Measures",
                    "Methods",
                    "Oseltamivir",
                    "Performance",
                    "RADx Tech",
                    "SARS-CoV-2 antigen",
                    "Symptoms",
                    "System",
                    "Time",
                    "United States Food and Drug Administration",
                    "Vaccines",
                    "clinical Diagnosis",
                    "portability",
                    "programs",
                    "rapid diagnosis",
                    "rapid testing",
                    "respiratory"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8102",
            "attributes": {
                "award_id": "75N93021C00012-0-9999-4",
                "title": "Statistical and Data Coordinating Center: SARS-CoV-2/COVID-19 Studies",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-03-01",
                "end_date": "2022-02-28",
                "award_amount": 2994239,
                "principal_investigator": {
                    "id": 23982,
                    "first_name": "MARIAN",
                    "last_name": "EWELL",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1673,
                            "ror": "",
                            "name": "THE EMMES COMPANY, LLC",
                            "address": "",
                            "city": "",
                            "state": "MD",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1673,
                    "ror": "",
                    "name": "THE EMMES COMPANY, LLC",
                    "address": "",
                    "city": "",
                    "state": "MD",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The goal of the Statistical and Data Coordinating Center is to provide comprehensive statistical support, data management and analysis activities for DMID-sponsored COVID clinical research trials. This includes internet-based electronic data collection, data management, data quality control and a specimen tracking system. In addition, the contractor provides consultation on statistics, study design, appropriate control groups, sample size, power calculations, randomization, stratification, and analysis.",
                "keywords": [
                    "2019-nCoV",
                    "COVID-19",
                    "Clinical Research",
                    "Clinical Trials",
                    "Consultations",
                    "Contractor",
                    "Control Groups",
                    "Data Analyses",
                    "Data Collection",
                    "Data Coordinating Center",
                    "Goals",
                    "Internet",
                    "Quality Control",
                    "Randomized",
                    "Research Design",
                    "Sample Size",
                    "Specimen",
                    "Stratification",
                    "System",
                    "base",
                    "coronavirus disease",
                    "data management",
                    "data quality",
                    "electronic data",
                    "research study",
                    "statistics"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8103",
            "attributes": {
                "award_id": "75N93021C00012-0-9999-3",
                "title": "Statistical and Data Coordinating Center: SARS-CoV-2/COVID-19 Studies",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-03-01",
                "end_date": "2022-02-28",
                "award_amount": 3994239,
                "principal_investigator": {
                    "id": 23982,
                    "first_name": "MARIAN",
                    "last_name": "EWELL",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1673,
                            "ror": "",
                            "name": "THE EMMES COMPANY, LLC",
                            "address": "",
                            "city": "",
                            "state": "MD",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1673,
                    "ror": "",
                    "name": "THE EMMES COMPANY, LLC",
                    "address": "",
                    "city": "",
                    "state": "MD",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The goal of the Statistical and Data Coordinating Center is to provide comprehensive statistical support, data management and analysis activities for DMID-sponsored COVID clinical research trials. This includes internet-based electronic data collection, data management, data quality control and a specimen tracking system. In addition, the contractor provides consultation on statistics, study design, appropriate control groups, sample size, power calculations, randomization, stratification, and analysis.",
                "keywords": [
                    "2019-nCoV",
                    "COVID-19",
                    "Clinical Research",
                    "Clinical Trials",
                    "Consultations",
                    "Contractor",
                    "Control Groups",
                    "Data Analyses",
                    "Data Collection",
                    "Data Coordinating Center",
                    "Goals",
                    "Internet",
                    "Quality Control",
                    "Randomized",
                    "Research Design",
                    "Sample Size",
                    "Specimen",
                    "Stratification",
                    "System",
                    "base",
                    "coronavirus disease",
                    "data management",
                    "data quality",
                    "electronic data",
                    "research study",
                    "statistics"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8108",
            "attributes": {
                "award_id": "1U19AI157797-01",
                "title": "Administrative Core",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-03-01",
                "end_date": "2026-02-28",
                "award_amount": 47167,
                "principal_investigator": {
                    "id": 22786,
                    "first_name": "SCOTT J.",
                    "last_name": "HULTGREN",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 827,
                            "ror": "",
                            "name": "WASHINGTON UNIVERSITY",
                            "address": "",
                            "city": "",
                            "state": "MO",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 827,
                    "ror": "",
                    "name": "WASHINGTON UNIVERSITY",
                    "address": "",
                    "city": "",
                    "state": "MO",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "PROJECT SUMMARY/ ABSTRACT: COVID-19 exemplifies the dire consequences of being unprepared for the next health crisis. One looming crisis involves the insidious rise of antibiotic resistant bacterial infections, necessitating the research described in our U19 application entitled “Innovative strategies to combat antibiotic-resistant infections” in response to RFA-AI-20-001 (Combating Antibiotic-resistant Bacteria Interdisciplinary Research Units (CARBIRU)). Our proposal is leveraged to translate basic science into new types of antibiotic-sparing medicines for common infections in the United States as well as common hospital-acquired infections. This U19 application utilizes a multi-departmental, multi-institutional, and interdisciplinary group of highly motivated microbiology, cell biology/physiology, immunology and medicinal chemistry researchers to develop antibiotic-sparing therapeutics and compounds that are capable of: i) treating common infections; and/or ii) increasing sensitivity to the current arsenal of available antibiotics. The Administrative Core (AC) will be responsible for coordinating the activities and monitoring the progress of the three research projects and the two scientific cores to achieve the overall goals of the U19 program. To accomplish this, the AC Leader, with the help of an Executive Committee comprising of the Leaders of the Research Projects and Cores, will oversee and coordinate the activities of the members of the Projects and Cores by: i) fostering frequent interactions; ii) supporting the exchange of data, methodologies, and ideas; iii) facilitating interactions with institutional and outside experts to gain advice for better functioning of the overall program and for translation of the program's findings into therapeutics development; and iv) coordinating financial and scientific progress reporting to granting agency staff. In addition, the AC will coordinate active participation in the U19 to ensure its overall success.",
                "keywords": [
                    "Affinity",
                    "Antibiotic Resistance",
                    "Antibiotics",
                    "Area",
                    "Attention",
                    "Bacteria",
                    "Bacterial Adhesins",
                    "Bacterial Antibiotic Resistance",
                    "Bacterial Infections",
                    "Basic Science",
                    "Budgets",
                    "COVID-19",
                    "Cellular biology",
                    "Centers for Disease Control and Prevention (U.S.)",
                    "Clinical",
                    "Collaborations",
                    "Combating Antibiotic Resistant Bacteria",
                    "Communication",
                    "Communication Methods",
                    "Development",
                    "Doctor of Philosophy",
                    "Electronic Mail",
                    "Ensure",
                    "Fostering",
                    "Funding",
                    "Goals",
                    "Grant",
                    "Guidelines",
                    "Health",
                    "Human",
                    "Immunology",
                    "Infection",
                    "Institution",
                    "Interdisciplinary Study",
                    "International",
                    "Journals",
                    "Leadership",
                    "Ligands",
                    "Medicine",
                    "Membrane",
                    "Methodology",
                    "Microbiology",
                    "Monitor",
                    "Monoclonal Antibodies",
                    "Multi-Drug Resistance",
                    "Nosocomial Infections",
                    "Pathogenicity",
                    "Peer Review",
                    "Persons",
                    "Pharmaceutical Chemistry",
                    "Physiology",
                    "Program Evaluation",
                    "Progress Reports",
                    "Publications",
                    "Regulation",
                    "Research",
                    "Research Personnel",
                    "Research Project Grants",
                    "Resource Sharing",
                    "Schedule",
                    "Scientist",
                    "Series",
                    "Site Visit",
                    "Teleconferences",
                    "Therapeutic",
                    "Translating",
                    "Translations",
                    "United States",
                    "United States National Institutes of Health",
                    "Wages",
                    "antibiotic resistant infections",
                    "combat",
                    "data exchange",
                    "design",
                    "improved functioning",
                    "individual responsibility",
                    "innovation",
                    "meetings",
                    "member",
                    "mimetics",
                    "pathogen",
                    "pathogenic bacteria",
                    "prevent",
                    "product development",
                    "programs",
                    "response",
                    "small molecule inhibitor",
                    "success",
                    "therapeutic development"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8111",
            "attributes": {
                "award_id": "273201600002I-0-759602100016-1",
                "title": "TASK ORDER 16: USE OF INHALED HYALURONAN IN PATIENTS WITH SEVERE COVID-19",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Environmental Health Sciences (NIEHS)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-03-01",
                "end_date": "2022-02-28",
                "award_amount": 225176,
                "principal_investigator": {
                    "id": 23985,
                    "first_name": "TAHARAT",
                    "last_name": "KHAN",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1675,
                            "ror": "",
                            "name": "SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",
                            "address": "",
                            "city": "",
                            "state": "MD",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1675,
                    "ror": "",
                    "name": "SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",
                    "address": "",
                    "city": "",
                    "state": "MD",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "COVID-19 is a potentially life-threatening infection by the coronavirus SARS-CoV2, which infects respiratory cells and induces epithelial injury, causing susceptible patients to develop adult respiratory distress syndrome (ARDS). ARDS leads to significant inflammation and accumulation of extracellular matrix (ECM), including hyaluronan (HA), a glycosaminoglycan sugar and abundant component of the lung ECM. HA is a powerful modulator of lung injury, inflammation and repair and is found in the airway lumen overlaying ciliated epithelial cells. Airway HA expression is induced by epithelial injury, including viral infection and recent reports highlight increased HA concentration in COVID-19 affected lungs as well. In cell culture and animal experiments we had found that therapeutic HA inhalation protects against SARS-CoV-2 infection. this study we explored the therapeutic role of HA COVID19-induced lung disease in patients with established moderate disease (admitted to hospital, in need for oxygen therapy). Specifically, we questioned whether inhaled HA may promote recovery from COVID19, since HA has antiviral, anti-inflammatory and pro-lung repair properties and ameliorates lung injury after a number of infectious and toxic exposures. We contracted with the Rome facility and initiated a study of inhaled HA (at least 10 days) or placebo. The outcomes were need for oxygen, and length of hospital stay.",
                "keywords": [
                    "2019-nCoV",
                    "Acute Respiratory Distress Syndrome",
                    "Adult",
                    "Adverse event",
                    "Affect",
                    "Animal Experiments",
                    "Anti-Inflammatory Agents",
                    "Antiviral Agents",
                    "COVID-19",
                    "COVID-19 treatment",
                    "Cell Culture Techniques",
                    "Cells",
                    "Clinical",
                    "Contracts",
                    "Control Groups",
                    "Coronavirus Infections",
                    "Disease",
                    "Epithelial Cells",
                    "Extracellular Matrix",
                    "Glycosaminoglycans",
                    "Hospitals",
                    "Hyaluronan",
                    "Immune response",
                    "Incidence",
                    "Inflammation",
                    "Inhalation",
                    "Inpatients",
                    "Intervention",
                    "Intervention Studies",
                    "Intubation",
                    "Investigation",
                    "Laboratories",
                    "Length of Stay",
                    "Life",
                    "Lung",
                    "Lung diseases",
                    "Outcome",
                    "Oxygen",
                    "Oxygen Therapy Care",
                    "Patients",
                    "Placebo Control",
                    "Placebos",
                    "Property",
                    "Randomized",
                    "Recovery",
                    "Reporting",
                    "Respiratory Failure",
                    "Role",
                    "Rome",
                    "SARS-CoV-2 infection",
                    "Safety",
                    "Serious Adverse Event",
                    "Steroids",
                    "Suspensions",
                    "Teaching Hospitals",
                    "Therapeutic",
                    "Time",
                    "Toxicant exposure",
                    "Virus Diseases",
                    "arm",
                    "clinical efficacy",
                    "efficacy evaluation",
                    "epithelial injury",
                    "inflammatory marker",
                    "lung injury",
                    "lung repair",
                    "prevent",
                    "pulmonary function",
                    "repaired",
                    "respiratory",
                    "severe COVID-19",
                    "sugar",
                    "ventilation",
                    "virology",
                    "ward"
                ],
                "approved": true
            }
        }
    ],
    "meta": {
        "pagination": {
            "page": 1392,
            "pages": 1442,
            "count": 14420
        }
    }
}